Cytek BioSciences Inc Stock News

Cytek has announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system.

FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL.

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Chad Wiatrowski - TD Cowen Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Bioscie...

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025.

The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109.37%. Cytek has reported net losses due to its growth strategy. In fact, in 2024, its operating expenses represented 65.67% of its sales. In 2024, the company reported cash and cash equivalents and marketable securities of $277.86 million. Meanwhile, its total liabilities...

Cytek Biosciences is showcasing its patented Full Spectrum Profiling™ technology at CYTO 2025 & American Association of Immunologists' (AAI) IMMUNOLOGY2025

There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitability potential, supported by effective cost management and a solid balance sheet. Despite a 41% YTD stock decline, Cytek's innovative FSP tech and growing Cytek Cloud user base signal strong future...

FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its resul...